Founder Effect and the Clinical and Molecular Characteristics in a Cohort of Classical and Non-Classical Congenital Lipoid Adrenal Hyperplasia (CLAH) due to StAR Mutations

Abdulsalam Abu-Libdeh 1 Ariella Weinberg-Shukron 2 Ephrat Levy-Lahad 2 David Zangen 1
1Division of Pediatric Endocrinology, Hadassah Hebrew University Medical Center
2Medical Genetics Institute, Shaare Zedek Medical Center

Introduction: Classical and non-classical congenital lipoid adrenal hyperplasia (CLAH) are caused by mutations in Steroidogenic Acute Regulatory Protein (StAR). The degree of enzyme activity impairment determines different clinical pictures.

Objective: To identify the genetic cause of Addisson’s disease in a cohort of 11 unrelated families with classical and non-classical CLAH, correlate the clinical and molecular characteristics and to identify a possible founder effect of these mutations.

Results: All (n=14) affected individuals with classical CLAH in Israel and the Palestinian territories had the N-terminal c.201_202delCT mutation due to a founder effect and presented neonatally with severe Addissonian crisis and XY-DSD responding well  to full replacement therapy. All (n=3) patients with non-classical CLAH had the G221S mutation (novel in the homozygous state), again with a founder effect. These patients presented during early childhood with addisonian crisis during a severe infection requiring just glucocorticoid replacement therapy. Characterization of the pubertal development in XX and XY patients of this cohort is underway.

Conclusion: Classical and non-classical CLAH due to StAR mutations are extremely rare but are significantly more common in the Palestinian population, given the founder effect of the 2 mutations characterized here. The different clinical phenotype of patients with classical and non-classical reflects the degree of StAR protein dysfunction caused by these mutations. To our knowledge, this is one of the largest cohorts studying the clinical and molecular characteristics of CLAH patients. The actual prevalence of mutations in the StAR gene in the general Palestinian population remains to be determined.









Powered by Eventact EMS